Clinical Trial Update: Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

View source ↗

Summary

An ongoing prospective, non-interventional post-authorization safety study for patients with unresectable differentiated thyroid carcinoma treated with sorafeni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Thyroid Carcinoma | Status: ACTIVE_NOT_RECRUITING